open access

Ahead of print
Original Article
Published online: 2021-08-26
Get Citation

Comparison of long-term clinical outcomes among zotarolimus-, everolimus-, and biolimus-eluting stents in acute myocardial infarction patients with renal impairment

Seok Oh, Dae Young Hyun, Kyung Hoon Cho, Ju Han Kim, Myung Ho Jeong
DOI: 10.5603/CJ.a2021.0099
·
Pubmed: 34490605

open access

Ahead of print
Original articles
Published online: 2021-08-26

Abstract

Background: It is important to determine the best drug-eluting stent (DES) for acute myocardial infarction (AMI) in patients with renal impairment. In this studythe outcomes of everolimus-eluting stents (EESs), zotarolimus-eluting stents (ZESs) and biolimus-eluting stents (BESs) were evaluated.

Methods: From the Korea Acute Myocardial Infarction-National Institutes of Health registry, a total of 1,470 AMI patients with renal impairment undergoing percutaneous coronary intervention (PCI) were enrolled (816 with EES, 345 with ZES, and 309 with BES). Renal impairment was defined as creatinine clearance < 60 mL/min/1.73 m2 estimated by the Cockcroft-Gault method. Major adverse cardiac and cerebrovascular events were determined as the composite of all-cause death, non-fatal myocardial infarction (MI), cerebrovascular accident, any revascularization, rehospitalization and stent thrombosis. All clinical outcomes were analyzed.

Results: The baseline characteristics of the patients revealed no significant difference between the three groups, except for Killip classification > 2, beta-blockers, lesion type, vascular approach, staged PCI, left main coronary artery (LMCA) complex lesions, LMCA PCI, and the number and length of implanted stents. In the Kaplan-Meier analysis, similar clinical outcomes were derived from the unadjusted data between the three DES groups. However, after the inverse probability of treatment weighting, a statistically significant difference was found in non-fatal MI, which implied a higher incidence of non-fatal MI in the ZES group than in the other two DES groups.

Conclusions: In AMI patients with renal impairment, there was no significant difference between the three stent groups in terms of long-term clinical outcomes, except for non-fatal MI.

Abstract

Background: It is important to determine the best drug-eluting stent (DES) for acute myocardial infarction (AMI) in patients with renal impairment. In this studythe outcomes of everolimus-eluting stents (EESs), zotarolimus-eluting stents (ZESs) and biolimus-eluting stents (BESs) were evaluated.

Methods: From the Korea Acute Myocardial Infarction-National Institutes of Health registry, a total of 1,470 AMI patients with renal impairment undergoing percutaneous coronary intervention (PCI) were enrolled (816 with EES, 345 with ZES, and 309 with BES). Renal impairment was defined as creatinine clearance < 60 mL/min/1.73 m2 estimated by the Cockcroft-Gault method. Major adverse cardiac and cerebrovascular events were determined as the composite of all-cause death, non-fatal myocardial infarction (MI), cerebrovascular accident, any revascularization, rehospitalization and stent thrombosis. All clinical outcomes were analyzed.

Results: The baseline characteristics of the patients revealed no significant difference between the three groups, except for Killip classification > 2, beta-blockers, lesion type, vascular approach, staged PCI, left main coronary artery (LMCA) complex lesions, LMCA PCI, and the number and length of implanted stents. In the Kaplan-Meier analysis, similar clinical outcomes were derived from the unadjusted data between the three DES groups. However, after the inverse probability of treatment weighting, a statistically significant difference was found in non-fatal MI, which implied a higher incidence of non-fatal MI in the ZES group than in the other two DES groups.

Conclusions: In AMI patients with renal impairment, there was no significant difference between the three stent groups in terms of long-term clinical outcomes, except for non-fatal MI.

Get Citation

Keywords

myocardial infarction, renal insufficiency, drug-eluting stents, zotarolimus, everolimus, biolimus

Supp./Additional Files (3)
Supplemental Table 1. Baseline clinical characteristics after IPTW adjustment
Download
59KB
Supplemental Table 2. Coronary angiography and procedural characteristics after IPTW adjustment
Download
58KB
Supplemental Table 3. Prevalence of previous history and LVEF < 40 % according to the creatinine clearance
Download
33KB
About this article
Title

Comparison of long-term clinical outcomes among zotarolimus-, everolimus-, and biolimus-eluting stents in acute myocardial infarction patients with renal impairment

Journal

Cardiology Journal

Issue

Ahead of print

Article type

Original Article

Published online

2021-08-26

DOI

10.5603/CJ.a2021.0099

Pubmed

34490605

Keywords

myocardial infarction
renal insufficiency
drug-eluting stents
zotarolimus
everolimus
biolimus

Authors

Seok Oh
Dae Young Hyun
Kyung Hoon Cho
Ju Han Kim
Myung Ho Jeong

References (46)
  1. Debella YT, Giduma HD, Light RP, et al. Chronic kidney disease as a coronary disease equivalent--a comparison with diabetes over a decade. Clin J Am Soc Nephrol. 2011; 6(6): 1385–1392.
  2. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351(13): 1296–1305.
  3. de Jager DJ, Grootendorst DC, Jager KJ, et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA. 2009; 302(16): 1782–1789.
  4. Sarnak MJ, Levey AS. Epidemiology, diagnosis, and management of cardiac disease in chronic renal disease. J Thromb Thrombolysis. 2000; 10(2): 169–180.
  5. Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994; 331(8): 496–501.
  6. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med. 1994; 331(8): 489–495.
  7. Moses JW, Leon MB, Popma JJ, et al. SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349(14): 1315–1323.
  8. Stone GW, Ellis SG, Cox DA, et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004; 350(3): 221–231.
  9. Virmani R, Guagliumi G, Farb A, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation. 2004; 109(6): 701–705.
  10. Kang SH, Chae IH, Park JJ, et al. Stent thrombosis with drug-eluting stents and bioresorbable scaffolds: evidence from a network meta-analysis of 147 trials. JACC Cardiovasc Interv. 2016; 9(12): 1203–1212.
  11. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting stents: is the paradigm shifting? J Am Coll Cardiol. 2013; 62(21): 1915–1921.
  12. Serruys PW, Farooq V, Kalesan B, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013; 6(8): 777–789.
  13. Natsuaki M, Kozuma K, Morimoto T, et al. Final 3-Year Outcome of a Randomized Trial Comparing Second-Generation Drug-Eluting Stents Using Either Biodegradable Polymer or Durable Polymer: NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-Eluting Stent Trial. Circ Cardiovasc Interv. 2015; 8(10): 815–818.
  14. Vlachojannis GJ, Smits PC, Hofma SH, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with coronary artery disease: three-year follow-up of the COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) trial. EuroIntervention. 2015; 11(3): 272–279.
  15. Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010; 375(9731): 2073–2081.
  16. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20): 2191.
  17. Kim JuH, Chae SC, Oh DJ, et al. Multicenter Cohort Study of Acute Myocardial Infarction in Korea-Interim Analysis of the Korea Acute Myocardial Infarction Registry-National Institutes of Health Registry. Circ J. 2016; 80(6): 1427–1436.
  18. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1): 31–41.
  19. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2019; 40: 87–165.
  20. Roffi M, Patrono C, Collet JP, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2015; 37(3): 267–315.
  21. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39: 119–77.
  22. Killip T, Kimball J. Treatment of myocardial infarction in a coronary care unit. Am J Cardiol. 1967; 20(4): 457–464.
  23. Yoshida K, Hernández-Díaz S, Solomon DH, et al. Matching Weights to Simultaneously Compare Three Treatment Groups: Comparison to Three-way Matching. Epidemiology. 2017; 28(3): 387–395.
  24. Jha V, Garcia-Garcia G, Iseki K, et al. Chronic kidney disease: global dimension and perspectives. Lancet. 2013; 382(9888): 260–272.
  25. Anavekar NS, McMurray JJV, Velazquez EJ, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351(13): 1285–1295.
  26. Foley RN, Murray AM, Li S, et al. Chronic kidney disease and the risk for cardiovascular disease, renal replacement, and death in the United States Medicare population, 1998 to 1999. J Am Soc Nephrol. 2005; 16(2): 489–495.
  27. Al Suwaidi J, Reddan DN, Williams K, et al. Prognostic implications of abnormalities in renal function in patients with acute coronary syndromes. Circulation. 2002; 106(8): 974–980.
  28. Wright RS, Reeder GS, Herzog CA, et al. Acute myocardial infarction and renal dysfunction: a high-risk combination. Ann Intern Med. 2002; 137(7): 563–570.
  29. Sarnak MJ, Levey AS, Schoolwerth AC, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Hypertension. 2003; 42(5): 1050–1065.
  30. Freeman RV, Mehta RH, Al Badr W, et al. Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors. J Am Coll Cardiol. 2003; 41(5): 718–724.
  31. Sørensen CR, Brendorp B, Rask-Madsen C, et al. The prognostic importance of creatinine clearance after acute myocardial infarction. Eur Heart J. 2002; 23(12): 948–952.
  32. Gupta J, Mitra N, Kanetsky PA, et al. CRIC Study Investigators. Association between albuminuria, kidney function, and inflammatory biomarker profile in CKD in CRIC. Clin J Am Soc Nephrol. 2012; 7(12): 1938–1946.
  33. Shlipak MG, Fried LF, Crump C, et al. Elevations of inflammatory and procoagulant biomarkers in elderly persons with renal insufficiency. Circulation. 2003; 107(1): 87–92.
  34. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int. 1999; 55(5): 1899–1911.
  35. Lutz J, Menke J, Sollinger D, et al. Haemostasis in chronic kidney disease. Nephrol Dial Transplant. 2014; 29(1): 29–40.
  36. Casserly L, Dember L. Thrombosis in end‐stage renal disease. Semin Dial. 2003; 16(3): 245–256.
  37. Luft FC. Renal disease as a risk factor for cardiovascular disease. Basic Res Cardiol. 2000; 95 Suppl 1: I72–I76.
  38. National Kidney Fundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis. 2002; 39: S1–S266.
  39. Sung SH, Chen TC, Cheng HM, et al. Comparison of clinical outcomes in patients undergoing coronary intervention with drug-eluting stents or bare-metal stents: a Nationwide Population Study. Acta Cardiol Sin. 2017; 33(1): 10–19.
  40. Chichareon P, Modolo R, Collet C, et al. Efficacy and safety of stents in ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2019; 74(21): 2572–2584.
  41. Kim YH, Her AY, Jeong MHo, et al. Two-year clinical outcomes of zotarolimus- and everolimus-eluting durable-polymer-coated stents versus biolimus-eluting biodegradable-polymer-coated stent in patients with acute myocardial infarction with dyslipidemia after percutaneous coronary intervention: data from the KAMIR. Heart Vessels. 2019; 34(2): 237–250.
  42. Choe JC, Cha KS, Jang HY, et al. Korea Acute Myocardial Infarction Registry Investigators. Outcomes of acute myocardial infarction patients implanted with biodegradable polymer biolimus-eluting stents versus new-generation durable polymer drug-eluting stents: a retrospective analysis. Angiology. 2017; 68(8): 698–706.
  43. Hachinohe D, Jeong MHo, Saito S, et al. Korea Acute Myocardial Infarction Registry Investigators. Comparison of drug-eluting stents in acute myocardial infarction patients with chronic kidney disease. Korean J Intern Med. 2012; 27(4): 397–406.
  44. Ahmed K, Jeong MHo, Chakraborty R, et al. Other Korea Acute Myocardial Infarction Registry Investigators. Comparison of zotarolimus- and everolimus-eluting stents in patients with ST-elevation myocardial infarction and chronic kidney disease undergoing primary percutaneous coronary intervention. J Cardiol. 2014; 64(4): 273–278.
  45. Koni E, Wanha W, Ratajczak J, et al. Five-Year comparative efficacy of everolimus-eluting vs. Resolute zotarolimus-eluting stents in patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Clin Med. 2021; 10(6).
  46. Iglesias JF, Muller O, Heg D, et al. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial. Lancet. 2019; 394(10205): 1243–1253.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: viamedica@viamedica.pl